How do I subscribe to ongoing alerts?

Subscribe to /feed/company/european-organisation-for-research-and-treatment-of-cancer-eortc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

European Organisation for Research and Treatment of Cancer - EORTC — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

European Organisation for Research and Treatment of Cancer - EORTC pipeline: 2 marketed, 0 filed, 11 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 11 Phase 3 4 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Pertuzumab + trastuzumab	Pertuzumab + trastuzumab	marketed	HER2-targeted monoclonal antibody combination	HER2 (human epidermal growth factor receptor 2)	Oncology
FLOT	FLOT	marketed	Chemotherapy regimen (combination)		Oncology
BEACOPP escalated q3 weeks	BEACOPP escalated q3 weeks	phase 3	Polychemotherapy regimen		Oncology
GM2-KLH vaccine	GM2-KLH vaccine	phase 3	Cancer vaccine	GM2 ganglioside	Oncology
monoclonal antibody BEC2	monoclonal antibody BEC2	phase 3	monoclonal antibody	GD3 ganglioside	Oncology
cMAB	cMAB	phase 3	PD-1 inhibitor	PD-1	Oncology
iMAB	iMAB	phase 3			Oncology
ABVD q4 weeks	ABVD q4 weeks	phase 3	Combination chemotherapy regimen		Oncology
Ra223	Ra223	phase 3	Alpha-emitting radiopharmaceutical	Bone matrix (calcium-mimetic mechanism)	Oncology
177Lu-PSMA-617	177Lu-PSMA-617	phase 3	Radioligand therapy / Targeted radionuclide therapy	PSMA (Prostate-Specific Membrane Antigen)	Oncology
approved GnRH agonist	approved GnRH agonist	phase 3
ISIS 3521	ISIS 3521	phase 3	Antisense oligonucleotide	Protein kinase C-alpha (PKC-alpha) mRNA	Oncology

Therapeutic area mix

Oncology · 11
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Celltrion · 2 shared drug classes
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · 2 shared drug classes
Asan Medical Center · 2 shared drug classes
Bristol-Myers Squibb · 2 shared drug classes
Hoffmann-La Roche · 2 shared drug classes
Huabo Biopharm Co., Ltd. · 2 shared drug classes
Amgen · 2 shared drug classes
Karolinska University Hospital · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for European Organisation for Research and Treatment of Cancer - EORTC:

Cite this brief

Drug Landscape (2026). European Organisation for Research and Treatment of Cancer - EORTC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/european-organisation-for-research-and-treatment-of-cancer-eortc. Accessed 2026-05-17.